Plasma tricyclic drug levels in amitriptyline-treated depressed patients |
| |
| Authors: | Donald S. Robinson M.D. Thomas B. Cooper C. Lewis Ravaris John O. Ives Alexander Nies Diantha Bartlett Kathleen R. Lamborn |
| |
| Affiliation: | (1) Department of Pharmacology, Marshall University School of Medicine, 25701 Huntington, W. Va., USA;(2) Department of Psychiatry, Marshall University, Huntington, W. Va., USA;(3) Departments of Psychiatry and Epidemiology, University of Vermont, Burlington, VT, USA;(4) Rockland Research Institute Laboratory, Orangeburg, New York, USA;(5) Department of Biostatistics, The Upjohn Company, Kalamazoo, MI, USA |
| |
| Abstract: | In a double-blind phenelzine controlled clinical trial, 49 depressed outpatients were treated with a fixed dose of amitriptyline (AMI) 150 mg/day for 6 weeks. No significant relationships were found between steady-state plasma levels of AMI and its metabolite, nortriptyline, at 4 weeks and therapeutic response at 6 weeks or side effects. In the patient subgroup with more severe endogenous symptoms, there was a general trend for a weak positive association between AMI plasma levels and clinical improvement. Plasma tricyclic determinations appear to have little if any predictive value for antidepressant effect in outpatients treated with AMI. |
| |
| Keywords: | Amitriptyline Plasma levels Depression Age Obesity |
| 本文献已被 SpringerLink 等数据库收录！ |
|
